Transformative
intranasal solutions

Mastering innovation to enhance patients and caregivers quality of life.

Scroll down
About us

Dianosic designs transformative intranasal solutions resolving patients adherence to medication challenges.

We collaborate with healthcare professionals in order to provide solutions that change patients’ lives in chronic rhinitis, chronic rhinosinusitis and intranasal bleeding (epistaxis).

Our ambitions

Maximize patients quality of life, supporting a rapid return to daily life activities.

Optimize efficacy and safety through low dose, targeted drug delivery.

Leverage our intranasal drug delivery platform to treat central nervous system diseases.

Reduce hospitalization time and frequency.

Our programs

Discover our future solutions in chronic rhinitis and chronic rhinosinusitis - The Active Resorbable Intranasal Scaffold (ARIS) platform

85% of allergic rhinitis patients are not compliant with their treatment.¹ In chronic rhinitis and chronic rhinosinusitis, 20% to 25% of patients do not respond to first line treatment.²

We create solutions to provide physicians and patients with minimally invasive non-surgical solutions that will solve patient adherence to medication.

ARIS – Nose To Brain

The NTB (Nose To Brain) program explores the significant therapeutic potential of using the intranasal route for drug delivery directly to the brain. This approach is based on our expertise in drug eluting polymers acquired with the ARIS scaffold development.

Learn more

Innovation center

Dianosic develops a platform of cutting-edge intranasal solutions based on a proprietary know-how in drug-eluting, long-term, resorbable polymer scaffolds. Based on state of the art academic research, we collaborate with renowned physicians in order to change the treatment paradigm for debilitating diseases.

Learn more
Latest News See all news

Stay tuned and follow us on social media.

Oct 10, 2024

Dianosic X WiSEED: Fundraising

See more
Feb 12, 2024

Dianosic shortlisted for the “Trophées des Entreprises Alsace 2024” award

See more
Feb 12, 2024

Dianosic x France Deeptech

See more

¹ Menditto E et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clin Exp Allergy. 2019 Apr;49(4):442-460. doi: 10.1111/cea.13333.

² The Role of Balloon Sinuplasty in the Treatment of Chronic Sinusitis. Cummings JP et al. JCOM. 2009; 16(1):30-6.